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The recent Health Technology Assessment international (HTAi) conference in Rome discussed how we can move ‘towards an integrated HTA framework for 
a more sustainable healthcare ecosystem’ and improve 
‘the role of multi-stakeholder involvement in HTA to face 
ethical dilemmas for health system’s economic, social and 
environmental sustainability.’1 
Evidence-informed deliberative processes (EDPs) to support 
priority setting for universal health coverage (UHC), as 
described in our editorial,2 are well-aligned with HTAi’s call 
for a more integrated HTA (or priority setting) framework. 
EDPs specifically achieve this by promoting early deliberation 
among a wide variety of stakeholders to identify, reflect and 
learn about the meaning and importance of values, informed 
by evidence on these values.2,3 Being a generic value-
assessment framework, it may be applied to prioritization 
exercises with either broad or narrow scopes and should be 
contextualized to its local setting. 
We agree with Gopinathan and Ottersen that the “focus of 
such processes [to support priority setting for UHC] should 
go beyond clinical services to accommodate also public 
health interventions.”4 We also concur with Lauer et al that 
priority setting should take into account higher level, systemic 
activities that can strengthen progression towards UHC such 
as ‘improving health-system governance,’ ‘ensuring equitable 
access to quality services,’ ‘separating prescribing from 
dispensing,’ or ‘setting up a pooled funding mechanism to 
purchase services.’5 Moreover, EDPs “should adapt to a diverse 
set of factors shaping the relationship between evidence and 
policy.”4 Ideally, EDPs are initiated at an early stage, as policy-
relevant evidence can still be commissioned or searched for 
during this stage, and there is still time to reflect on input 
or ideas put forward by stakeholders. As Gopinathan and 
Ottersen point out, this requires involvement of the right 
stakeholders, including non-health stakeholders where 
relevant.4 At the same time, Lauer et al raise the question “who 
should be invited to the deliberative dialogue?”5 We argue 
that those affected by decisions should at least be provided 
the opportunity to participate and provide relevant reasons or 
evidence3 – and we acknowledge that it is hard to determine 
who the relevant stakeholders are, and that standardized 
approaches are required to identify and engage relevant 
stakeholders. The description by Gopinathan and Ottersen of 
the complex relationship between evidence and policy further 
demonstrates the challenge of knowledge translation and how 
evidence can eventually be presented so as to facilitate its 
uptake and inclusion in policy formulation or revision.6 More 
broadly speaking, these comments highlight the challenge 
of institutionalization: how to work towards a situation 
that priority setting for UHC gets integrated in the routine 
decision making processes at both national and sub-national 
levels. 
With regard to whether stakeholder deliberation as part 
of EDPs departs from a ‘blank slate,’ we agree with Lauer 
et al that countries should not ignore global level policy as 
formulated and endorsed by the World Health Organization 
(WHO) member states.5 Universal goals do need to be 
aligned with local context and priorities. We also recognize 
the point made by Lauer et al that EDPs, generic as they are, 
are already in place to a certain degree at the country level 
and are supported by the WHO Secretariat,5 in the form of 
consultative groups, and part of health-sector reviews and 
strategic planning and budgeting. Likewise, as Chalkidou et al 
point out, the International Decision Support Initiative (http://
www.idsihealth.org/) has been established to strengthen in-
country institutional and technical capacity together with 
open participative processes for evidence-informed policy-
making.7 We hope that such initiatives will benefit from the 
further development of EDPs.
That said, it is not our intention to devalue cost-effectiveness 
evidence in itself – or to criticize agencies specialized 
in producing this particular type of evidence.5,7 On the 
contrary, evidence on the cost-effectiveness of a clinical or 
public health intervention provides relevant information 
on the opportunity costs of alternative investments that are 
foregone. Hence we do not oppose, but instead welcome 
efforts to integrate evidence on multiple criteria as is the 
case in the extended cost-effectiveness analysis approach.5,8,9 
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Nevertheless, we agree with Chalkidou et al and would like to 
highlight again that “global approaches to CEA can hardly be 
too context-sensitive” for the very reason that “studies done 
by global players that ignore local contexts but nonetheless 
presume to advise may undermine local priorities and distort 
local spending decisions.”7 We furthermore applaud WHO 
for providing broader support and guidance to countries.5 
Yet, we observe in practice that cost-effectiveness is often 
considered the dominant criterion when used in priority 
setting. This effectively makes the generation of other 
evidence and deliberation on additional criteria secondary 
to cost-effectiveness, which may undermine the legitimacy of 
decisions at the country level. 
We thank all authors who commented on our editorial, and we 
look forward to working together in the coming years to help 
harmonize EDPs with like-minded initiatives and align them 
with sustainable country-led decision-making processes.
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